A Phase 2 Multicenter Clinical Trial of Intraoperative Molecular Imaging of Lung Cancer with a pH-Activatable Nanoprobe

Gregory T. Kennedy,Feredun S. Azari,Austin Chang,Patrick Bou-Samra,Charuhas Desphande,Jarrod Predina,Edward J. Delikatny,Madeline Olson,David C. Rice,Sunil Singhal
DOI: https://doi.org/10.1007/s11307-024-01933-x
2024-07-13
Molecular Imaging and Biology
Abstract:Intraoperative molecular imaging (IMI) uses tumor-targeted optical contrast agents to improve identification and clearance of cancer. Recently, a probe has been developed that only fluoresces when activated in an acidic pH, which is common to many malignancies. We report the first multicenter Phase 2 trial of a pH-activatable nanoprobe (pegsitacianine, ONM-100) for IMI of lung cancer.
radiology, nuclear medicine & medical imaging
What problem does this paper attempt to address?